Developing new methods to create specialized peptides for drug discovery
New catalytic strategies to make non-proteinogenic peptides
This study is looking at new ways to create better medications by using special building blocks called non-proteinogenic amino acids to make peptides that can more effectively target important receptors in our bodies, which could help develop new treatments for various health conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Lawrence NIH-funded |
| Lab location | 1 site (Lawrence, United States) |
| Project ID | NIH-11086619 on NIH RePORTER |
What this research studies
This research focuses on improving the development of drugs that target G protein-coupled receptors (GPCRs), which are crucial in many medical treatments. By using non-proteinogenic amino acids (NPAAs) in peptide synthesis, the research aims to enhance the effectiveness and properties of these peptides as potential medications. The approach involves creating diverse peptide libraries through innovative chemical synthesis techniques, allowing for a more thorough exploration of how these peptides interact with GPCRs. This could lead to the discovery of new drugs that better modulate GPCR activity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that could benefit from improved GPCR-targeting therapies, such as those related to metabolic disorders or certain cancers.
Not a fit: Patients with conditions unrelated to GPCRs or those who do not respond to peptide-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective medications for conditions treated by GPCR-targeting drugs.
How similar studies have performed: Previous research has shown promise in using non-proteinogenic amino acids to enhance peptide drug properties, indicating a potential for success in this novel approach.
Where this research is happening
Lawrence, United States
- University of Kansas Lawrence — Lawrence, United States (Active)
Researchers
- Principal investigator: Bloom, Steven — University of Kansas Lawrence
- Study coordinator: Bloom, Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.